AKT1 and breast carcinoma: By contrast, the authors also found that a WT AKT1 breast cancer xenograft model displayed reduced sensitivity to compound 4, but showed higher sensitive to ARQ092 and capivasertib, both of them are regular pan-AKT inhibitors.